Please sign in to follow a disease.
New study aims to predict best treatments for rheumatoid diseases using AI and health data
NCT ID NCT06235684
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study will collect health information, samples, and data from 100 people in Luxembourg (800 total across Europe) who have rheumatoid diseases and are starting or changing treatment. Researchers hope to find patterns that can predict which treatments work best for each person. The goal is to improve personalized medicine and better understand these diseases.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which treatment will work best for each patient with rheumatoid diseases, leading to more personalized care.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not find clear markers, and results may take years to impact patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2032
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: ● Signed informed consent form * ≥ 18 years of age * Willing and able to comply with the protocol for the duration of the study including data and samples collection, study visits and examinations * Either newly diagnosed with a RD as defined in the diseases of interest below\* requiring initiation of therapy OR treatment change , as per physician's discretion OR any increase in disease activity assessed by the rheumatologist to be relevant (e.g., flare(s) before the study visit) \*For RA: * Participants fulfilling the 2010 ACR/EULAR criteria for RA * Newly diagnosed RA in the last 2 years requiring initiation/change of therapy OR any type of RA requiring treatment change * For SLE: * Participants fulfilling the 2019 ACR/EULAR Classification Criteria of Systemic Lupus Erythematosus (SLE) * For SSc: • Participants fulfilling the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis (Ssc) * For ASSD: * Participants fulfilling the 2010 Connor's criteria for ASSD Exclusion criteria 1. Any condition that could potentially hamper the compliance with the study protocol, including study procedures and study visits (such as mental disability that makes it difficult or impossible to answer questionnaires) 2. Not fluent in any of the following languages: French, English or German 3. Known pregnancy Note: If the participant is pregnant after inclusion and/or follow-up, this is not a reason for withdrawal. 4. Participation in a prospective randomised interventional trial 5. Decrease of disease activity 6. Treatment change due to the unavailability of medication 7. Treatment change due to safety reasons 8. Disease-specific exclusion criteria: For RA: • overlap of RA with any other rheumatic/immunologic disease For SLE: * overlap of SLE with any other rheumatic/immunologic disease For SSc: * overlap of SSc with any other rheumatic/immunologic disease * other forms of SSc than diffuse cutaneous or limited cutaneous systemic sclerosis For ASSD: * overlap of ASSD with any other rheumatic/immunologic disease * other forms of myositis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Antisynthetase syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ear-Zapping device may quiet lupus pain and fatigue
- A new ankle? researchers track 400 people with an implant meant to restore movement
- Can a weekly dipstick at home catch lupus kidney damage early?
- Can a Job-Focused rehab program keep arthritis patients employed?
- Inhaled xenon gas could reveal hidden lung vessel disease without catheter
- Do rheumatic diseases quietly damage the Eye's oil glands?